AmplifyBio
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
AmplifyBio was an Ohio-based cell and gene therapy contract development and manufacturing organization (CDMO). Spun out of Battelle in May 2021 with $200 million in financing from Battelle, Narya Capital, Viking, and Casdin Capital, it provided research and manufacturing services to drug makers, including preclinical CRO work and cell and gene therapy development. It operated a $200 million facility in West Jefferson, Ohio, acquired a site in South San Francisco in 2022, and opened a 350,000-square-foot manufacturing plant in New Albany in late 2023.
02 / AmplifyBio FAILURE REASONS
Failure factors supported by the current evidence
AmplifyBio stated on its website that it shut operations after months of efforts by leadership, investors, and other stakeholders to explore and exhaust all investment and acquisition possibilities.
The company said it exhausted investment possibilities before closing.
The company said it exhausted acquisition possibilities before closing.
03 / EVENT HISTORY
Events in the structured record
- Product or service closed
AmplifyBio announced on 4 Apr 2025 that it had shut down operations after four years; The Pharma Navigator (14 Apr 2025) reported the company website statement.
- Bankruptcy
PACER Monitor records AmplifyBio, LLC bankruptcy restructuring case 2:25-bk-52140 in the U.S. Bankruptcy Court for the Southern District of Ohio, filed 16 May 2025, plan confirmed 29 Oct 2025.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
In December 2024, AmplifyBio began cost-cutting: it closed its South San Francisco R&D site and laid off employees in its Ohio-based preclinical CRO business, consolidating operations into Ohio.
- 02
On April 4, 2025, AmplifyBio announced the closure of its operations, saying months of efforts by leadership, investors, and stakeholders to find investment or acquisition options had been exhausted.
- 03
In May 2025, AmplifyBio, LLC filed for Chapter 11 bankruptcy in Columbus, Ohio, among the large bankruptcy filings recorded by Bloomberg for the week ending May 17, 2025.